CN107485618A - The medicine of knee joint intracavitary administration local soaking formula targeted therapy meniscus injury - Google Patents
The medicine of knee joint intracavitary administration local soaking formula targeted therapy meniscus injury Download PDFInfo
- Publication number
- CN107485618A CN107485618A CN201610408841.5A CN201610408841A CN107485618A CN 107485618 A CN107485618 A CN 107485618A CN 201610408841 A CN201610408841 A CN 201610408841A CN 107485618 A CN107485618 A CN 107485618A
- Authority
- CN
- China
- Prior art keywords
- medicine
- meniscus
- knee joint
- branch
- targeted therapy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/04—X-ray contrast preparations
- A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
- A61K49/0438—Organic X-ray contrast-enhancing agent comprising an iodinated group or an iodine atom, e.g. iopamidol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to field of medical technology, more particularly to a kind of knee joint intracavitary administration local soaking formula targeted therapy meniscus injury medicine, medicine to be made up of following component and dosage：Polymer hyaluronic acid sodium 25mg × 2,2ml/ branch；Lincomycin 0.6g × 2,5ml/ branch；Dexamethasone 5mg × 2,1ml/ branch；Physiological saline 10ml × 1；This compounding pharmaceutical mainly by the medicines such as polymer hyaluronic acid sodium, lincomycin, dexamethasone, physiological saline according to or not exclusively formed according to certain composition and dosage, matching medication is nonionic diodone solution and lidocaine, the medicine can organically combine with a variety of meniscus diagnosis and treatment means, realize that simple and safe, practicality and high efficiency, curative effect are reliable, can effectively treat meniscus injury.
Description
Technical field
The present invention relates to a kind of medicine preparation for treating injury of meniscus of knee joint, a variety of medicines press certain use
Amount and Function Mixture together with, achieve treat meniscus injury new role.New drug main component includes macromolecule hyalomitome
Sour sodium, dexamethasone, lincomycin, auxiliary element are physiological saline, nonionic iodine solution contrast agent, lidocaine anesthesia
Agent.A variety of drug ingedients function and effect in the treatment of meniscus injury is different, has got operation collaboration and has made
The new role improved with, meniscus therapeutic effect.
Background technology
The diagnosis of injury of meniscus of knee joint at present relies primarily on clinical examination, Magnetic resonance imaging art and Arthroscopy
Look into.Inspection fee is higher, checks that wound is larger.Its therapeutic scheme, which is generally taken, extracts repairing or displacement under meniscus or arthroscope
The invasive operations such as artificial meniscus, operation wound is big, cure rate, obvious effective rate are not ideal enough, may occur in which joint instability in the recent period, far
Phase can concurrent traumatic arthritis etc..Because meniscus center is without blood vessel supply nutrition, therefore conservative treatment is ineffective.On half
Whether the diagnosis of month dash-board injury, make diagnosis the fifties in last century by pneumoarthrography of knee art to meniscus injury；60 years
In generation, is improved to use idodine and air double contrast radiograph；There is arthroscope direct-view lower check the seventies to diagnose；Until in the eighties
Phase just has Magnetic resonance imaging art to diagnose meniscus injury.
Self-heal is unable to after meniscus tear.At present the therapeutic modality that generally uses of the country be surgical removal or
Looked at straight down with arthroscope and make partial meniscectomy or repairing, there is the shortcomings that wound is big, cure rate and obvious effective rate are not bery preferable,
It in the recent period can the complication such as concurrent joint instability, easily concurrent traumatic arthritis at a specified future date.
Also it is a kind of individually medicine can repair meniscus completely or be completely torn apart simultaneously and can treat articular cavity
Interior sepage, inflammation and adhesion.
In consideration of it, applicant it is innovative first develop a kind of compounding pharmaceutical of new meniscus part targeted therapy,
Drug therapy for complication in meniscus injury and its articular cavity opens new road.
The content of the invention
In view of above-mentioned technical problem, applicant has invented a kind of knee joint intracavitary administration local soaking formula targeted therapy half
The composition of medicine of month dash-board injury, mainly polymer hyaluronic acid sodium in medicine, while be mixed with can treatment of arthritis ground plug
Meter Song, lincomycin, it is sent to plus microtubular in the nonionic diodone guidance cavity of normal saline dilution around meniscus,
The lidocaine of local anaesthesia effect is also equipped with, the hybrid medicine of the preparation repairs damage first quarter moon similar to joint prosthesis synovia
The main component of plate is polymer hyaluronic acid sodium, and this medicine is prepared can be with other a variety of organic knots of meniscus diagnosis and treatment means
Close, realize that simple and safe, practicality and high efficiency, curative effect are reliable, can effectively treat meniscus injury, particularly treat meniscus damage
The complication of wound, including micro- bleeding inflammatory or courageous and upright mixing sepage in articular cavity, arthritis, adhesion etc. in articular cavity.
Technical scheme is used by the present invention solves above-mentioned technical problem：
A kind of medicine of knee joint intracavitary administration local soaking formula targeted therapy meniscus injury, it is characterised in that described
Medicine is made up of following component ratio：
Lot number：H10960136, polymer hyaluronic acid sodium 25mg × 2,2ml/ branch；
Lot number：H50020209, lincomycin 0.6g × 2,5ml/ branch；
Dexamethasone 5mg × 2；1ml/ branch；
Lot number：H31021690 physiological saline, 10ml × 1.
Whole hybrid medicine dosage about 25-30ml, all squeeze into every time around the meniscus of joint Intraluminal lesions.
Alternatively use, dosage is non-constant, above-mentioned knee joint intracavitary administration local soaking formula targeted therapy half
Month dash-board injury medicine, include the nonionic Iohexol contrast agent of lot number H20053800 300 concentration, each general 5-
10ml。
Alternatively use, dosage is non-constant, above-mentioned knee joint intracavitary administration local soaking formula targeted therapy half
Month dash-board injury medicine, also included lot number are H1507052 2% lidocaine, as local anaesthesia medication, each general 2-
5ml。
The technical scheme that said medicine is prepared has the following advantages that or beneficial effect：
The invention discloses a kind of knee joint intracavitary administration local soaking formula targeted therapy meniscus injury medicine, is mainly
It is made up of medicines such as polymer hyaluronic acid sodium, lincomycin, dexamethasone, water according to certain component ratio, the medicine can
To be organically combined with a variety of meniscus diagnosis and treatment means, realize that simple and safe, practicality and high efficiency, curative effect are reliable, can effectively treat
Meniscus injury.
Embodiment
With reference to specific embodiment, the present invention is further illustrated, but not as limiting to the invention.
Meniscus be stabilized knee labyrinth in indispensable part, its function conclude have following six
Point：Concussion can be absorbed, plays cushioning effect；Meniscus is in the filling of wedge, increases connecing indirectly between condyle of femur and tibial condyle
Contacting surface is accumulated, and can prevent the insertion of synovial bursae or synovial membrane；Deepen shin bone facies artieularis malleolaris, stabilization is risen to knee joint；Assist control
Make kneed front and rear, side and rotary moveable.Can occur the front inner rotation is unstable after Meniscectomy；The work of meniscus
It is dynamic to be uniformly distributed synovia, lubricating joint is served favourable.After cutting off meniscus, kneed frictional force increase
20%；According to surveying and determination, knee joint physiology loading surface is 23 square centimeters, more than condyle of femur and the contact surface of tibial condyle, therefore meniscus
There is the function of directly bearing a heavy burden.
Embodiment one：
In consideration of it, applicant has applied for patent of invention in novelty：A kind of knee joint intracavitary administration local soaking formula target
To treatment meniscus injury medicine, it is characterised in that the medicine is made up of following component ratio：Polymer hyaluronic acid sodium 25mg
× 2,2ml/ branch；
Lincomycin 0.6g × 2,5ml/ branch；
Dexamethasone 5mg × 2；1ml/ branch；
0.9% physiological saline 10ml × 1.
In the present invention one preferably but in non-limiting embodiment, the targeting of above-mentioned knee joint intracavitary administration local soaking formula
Meniscus injury medicine is treated, includes the nonionic Iohexol contrast agent of lot number H20053800 300 concentration, every time one
As 5-10ml.
In the present invention one preferably but in non-limiting embodiment, the targeting of above-mentioned knee joint intracavitary administration local soaking formula
Meniscus injury medicine is treated, also included lot number is H1507052 2% lidocaine, as local anaesthesia medication, every time
General 2-5ml.
By above-mentioned whole hybrid medicine dosage about 25-30ml, all squeeze into every time around the meniscus of joint Intraluminal lesions
It can be used to successive treatment.
Embodiment two：Essentially identical with embodiment one, its main distinction is described various drug doses proportioning
Difference, it is not described in detail herein, even if but it should be understood by those skilled in the art that being that dosage ratio appearance fine setting is also
Reasonably fluctuate according to specific circumstances, have no effect on the essentiality content of patent of the present invention.
In summary, the invention provides a kind of knee joint intracavitary administration local soaking formula targeted therapy meniscus injury medicine
Thing, mainly it is made up of medicines such as polymer hyaluronic acid sodium, lincomycin, dexamethasone, water according to certain component ratio,
The medicine can organically combine with a variety of meniscus diagnosis and treatment means, realize that simple and safe, practicality and high efficiency, curative effect are reliable, Ke Yiyou
The treatment meniscus injury of effect.
It should be appreciated by those skilled in the art that the different pharmaceutical composition in above compounding pharmaceutical can be according to patient's condition, its
Ratio can change, and particularly the dosage of physiological saline and contrast agent can change according to different situations.Such change ratio
Example has no effect on the substantive content of the present invention.
It is to be appreciated that the present invention is not limited to the above specific embodiments, wherein the equipment not being described in detail to the greatest extent
It is construed as being practiced with the common mode in this area with structure；Any those skilled in the art, do not taking off
From under technical solution of the present invention ambit, all technical solution of the present invention is made using the methods and technical content of the disclosure above
Go out many possible changes and modifications, or be revised as the equivalent embodiment of equivalent variations, this is had no effect in the essence of the present invention
Hold.Therefore, every content without departing from technical solution of the present invention, the technical spirit according to the present invention is to made for any of the above embodiments
Any simple modifications, equivalents, and modifications, still fall within technical solution of the present invention protection in the range of.
Claims (3)
- A kind of 1. medicine of knee joint intracavitary administration local soaking formula targeted therapy meniscus injury, it is characterised in that the medicine Thing is made up of following component ratio：Polymer hyaluronic acid sodium 25mg × 2,2ml/ branch；Lincomycin 0.6g × 2,5ml/ branch；Dexamethasone 5mg × 2；1ml/ branch；Physiological saline 10ml × 1.
- 2. the medicine of knee joint intracavitary administration local soaking formula targeted therapy meniscus injury according to claim 1, its It is characterised by, the medicine also includes 300 concentration nonionic Iohexol contrast agent.
- 3. the medicine of knee joint intracavitary administration local soaking formula targeted therapy meniscus injury according to claim 1, its It is characterised by, the medicine also includes 2% lidocaine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610408841.5A CN107485618A (en) | 2016-06-12 | 2016-06-12 | The medicine of knee joint intracavitary administration local soaking formula targeted therapy meniscus injury |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610408841.5A CN107485618A (en) | 2016-06-12 | 2016-06-12 | The medicine of knee joint intracavitary administration local soaking formula targeted therapy meniscus injury |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107485618A true CN107485618A (en) | 2017-12-19 |
Family
ID=60642747
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610408841.5A Pending CN107485618A (en) | 2016-06-12 | 2016-06-12 | The medicine of knee joint intracavitary administration local soaking formula targeted therapy meniscus injury |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107485618A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102614211A (en) * | 2011-12-30 | 2012-08-01 | 龚磊 | Novel pharmaceutical usage of lincomycin |
| CN102631364A (en) * | 2011-12-30 | 2012-08-15 | 龚磊 | Application of lincomycin in medicine for treating meniscus injury |
-
2016
- 2016-06-12 CN CN201610408841.5A patent/CN107485618A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102614211A (en) * | 2011-12-30 | 2012-08-01 | 龚磊 | Novel pharmaceutical usage of lincomycin |
| CN102631364A (en) * | 2011-12-30 | 2012-08-15 | 龚磊 | Application of lincomycin in medicine for treating meniscus injury |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Pollock et al. | The use of arthroscopy in the treatment of resistant frozen shoulder | |
| Edelson et al. | Short-Term Effects of Knee Washout for Osteoarth ritis | |
| US20100196281A1 (en) | Use of resiniferatoxin (rtx) for producing an agent for treating joint pains and method for applying said agent | |
| CN105263500A (en) | Bone-selective osteogenic oxysterol-bone targeting agents | |
| JP2000501740A (en) | Lubricants with phospholipids and propylene glycol | |
| JP2008524267A (en) | Mixtures of vanilloid receptor agonists and nerve regeneration substance inhibitors, their use to produce analgesics, and methods of applying the analgesics | |
| CN105960230A (en) | Aqueous based capsaicinoid formulations and methods of manufacture and use | |
| Tagliafico et al. | Ultrasound-guided interventional procedures around the shoulder | |
| CN1859918B (en) | Use of hyaluronic acid for treating acute and overuse sprain and strain | |
| AU2009304002B2 (en) | A medicinal product and treatment | |
| JP5080983B2 (en) | Use of vanilloid receptor agonist together with glycolose aminoglycan or proteoglycan for the manufacture of a medicament for the treatment of joint pain and method of applying said medicament | |
| RU2433844C1 (en) | Method of treating degeneratively-dystrophic diseases of musculoskeletal system and posttraumatic pain syndromes | |
| US20220125848A1 (en) | Method for treating osteoarthritis with a combination of mesenchymal stem cell exosomes, synovial mesencymal stem cells, and scaffolds | |
| CN107485618A (en) | The medicine of knee joint intracavitary administration local soaking formula targeted therapy meniscus injury | |
| KR20190116636A (en) | Composition for regenerating cartilage comprising polydeoxyribonucleotide and hyaluronic acid | |
| Erkocak et al. | Intraarticular local anesthetics: primum non nocere | |
| RU2299733C1 (en) | Method for treating patients for degenerative dystrophy diseases of locomotor apparatus and post-traumatic commissure processes | |
| US20070142480A1 (en) | Alleviation of pain in osteoarthritis by means of intra-articular implantation of perfluorodecalin. | |
| KR20120095451A (en) | A combination for the treatment of osteoarthritis | |
| Lucena et al. | Analgesic and anti-edematogenic effects of oral trypsin were abolished after subdiaphragmatic vagotomy and spinal monoaminergic inhibition in rats | |
| Buryanov et al. | Prevention and treatment of posttraumatic osteoarthrosis in patients with intraarticular osteochondral fractures | |
| Ara et al. | Effect of Various Treatment Modalities After Spinal Cord Injury | |
| Giri | clinical case letter | |
| RU2377974C2 (en) | External preparation for treating arthropathies and soft tissue conditions | |
| Touma et al. | Topical nonsteroidal anti-inflammatory drugs in the treatment of osteoarthritis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20171219 |